2023
DOI: 10.9740/mhc.2023.10.244
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports

Alejandro Del Rio Verduzco,
Ahva Salari,
Parna Haghparast

Abstract: Introduction Chronic insomnia affects 5% to 10% of the US population, increasing the demand for treatment options and the corresponding research to prove their validity.1 This review compares recommendations from 3 clinical guidelines and summarizes hypnotic medications, including their newly reported side effects not mentioned in the guidelines. In addition, we aim to provide an overview of what pharmacotherapies are available for prescribers and patients. … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 40 publications
0
0
0
Order By: Relevance
“…Lemborexant 5 mg and 10 mg demonstrated statistically significant superiority (p < 0.05) on the primary efficacy measure, LPS, compared to placebo, and also demonstrated statistically significant improvement in SEF and WASO compared to placebo. Additionally, DORAs appear to promote both rapid eye movement (REM) and non-REM sleep, whereas GABA-A agonists, such as benzodiazepines (BZDs) and Z-drugs, promote only non-REM sleep [44]. The most common adverse effect of lemborexant is drowsiness, while serious side effects may include decreased daytime alertness, impaired ability to operate a vehicle, sleep paralysis, hallucinations, complex sleep behaviors, and worsening depression and suicidal thoughts [42,43,45].…”
Section: Lemborexant For Insomniamentioning
confidence: 99%
“…Lemborexant 5 mg and 10 mg demonstrated statistically significant superiority (p < 0.05) on the primary efficacy measure, LPS, compared to placebo, and also demonstrated statistically significant improvement in SEF and WASO compared to placebo. Additionally, DORAs appear to promote both rapid eye movement (REM) and non-REM sleep, whereas GABA-A agonists, such as benzodiazepines (BZDs) and Z-drugs, promote only non-REM sleep [44]. The most common adverse effect of lemborexant is drowsiness, while serious side effects may include decreased daytime alertness, impaired ability to operate a vehicle, sleep paralysis, hallucinations, complex sleep behaviors, and worsening depression and suicidal thoughts [42,43,45].…”
Section: Lemborexant For Insomniamentioning
confidence: 99%